IP Verse

Maropitant Formulation - EP3173071

The patent EP3173071 was granted to LE VET on Mar 24, 2021. The application was originally filed on Nov 28, 2016 under application number EP16200848A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3173071

LE VET
Application Number
EP16200848A
Filing Date
Nov 28, 2016
Status
Granted And Under Opposition
Feb 19, 2021
Publication Date
Mar 24, 2021
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

KRKADec 23, 2021HOFFMANN EITLEADMISSIBLE
HOFFMANN EITLEDec 20, 2021HOFFMANN EITLEADMISSIBLE

Patent Citations (10) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONWO2005082416
DESCRIPTIONWO9005729
OPPOSITIONCN103637987
OPPOSITIONEP1800689
OPPOSITIONJPS6340166
OPPOSITIONWO2005082416
OPPOSITIONWO2013078500
OTHERWO2005082416
SEARCHWO2005082416
SEARCHWO2013078500

Non-Patent Literature (NPL) Citations (24) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
DESCRIPTION- European Pharmacopoeia 8.0, (201101), page 50103
DESCRIPTION- LUI; RONG, Water-insoluble Drug Formulation, CRC PRESS, (2008), page 180
DESCRIPTION- USP Pharmacists' Pharmacopoeia, (20091201), page S5,38
OPPOSITION- Anonymous, "CVMP assessment report for Cerenia new route of administration (intravenous use) for the solution for injection (EMEA/V/C/000106/X/0023)", EMEA, (20150410), pages 1/12 - 2/12, EMEA, URL: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/veterinary/000106/WC500189398.pdf, (20170322), XP055357742
OPPOSITION- Anonymous, "SCIENTIFIC DISCUSSION of Cerenia", EMA, (20040101), pages 1 - 22, EMA, URL: https://www.ema.europa.eu/en/documents/scientific-discussion/cerenia-epar-scientific-discussion_en.pdf, (20220114), XP055879195
OPPOSITION- Broadhead J, Gibson, M, "Chapter 9: Parenteral Dosage Forms", Pharmaceutical Preformulation and Formulation: A Practical Guide from Candidate Drug Selection to Commercial Dosage Form, CRC Press, (20090101), vol. 199, pages 325 - 347, XP055882149
OPPOSITION- Broadhead Joanne, "Chapter 9 Parenteral Dosage Forms", Pharmaceutical Preformulation and Formulation, (20090101), pages 331 - 354, XP055879181
OPPOSITION- Isabella Merola, Daniel S Mills, "Systematic review of the behavioural assessment of pain in cats ", Journal of Feline Medicine and Surgery, (20160101), vol. 18, no. 2, pages 60 - 76, XP055890346
OPPOSITION- John M. Williams, Nathan R. Howe, "Benzyl Alcohol Attenuates the Pain of Lidocaine Injections and Prolongs Anesthesia", J Dermatologic Surgery Oncol., (19940101), vol. 20, pages 730 - 733, XP055890357
OPPOSITION- Kappelgaard Anne-Marie, Et Al, " Liquid Growth Hormone: Preservatives and Buffers", Hormone Research in Paediatrics, (20040101), vol. 62, no. 3, pages 98 - 103, XP055879193
OPPOSITION- Lofti El Bahri, "Maropitant: A novel treatment for acute vomiting in dogs", (20090901), pages 1 - 5, URL: https://www.dvm360.com/view/maropitant-novel-treatment-acute-vomiting-dogs, (20220210), XP055890335
OPPOSITION- Michel J. Belliveau, David R. Jordan, "Minimizing injection pain", CMAJ, (20121016), vol. 184, no. 15, page 1715, XP055890366
OPPOSITION- RASMUSSEN L H; ZACHMANN M; NILSSON P, "AUTHENTIC RECOMBINANT HUMAN GROWTH HORMONE RESULTS OF A MULTICENTER CLINICAL TRIAL IN PATIENTS WITH GROWTH HORMONE DEFICIENCY", HELVETICA PAEDIATRICA ACTA, SCHWABE, BASEL, CH, CH , (19880101), vol. 43, no. 5-6, ISSN 0018-022X, pages 443 - 448, XP009158145
OPPOSITION- Robert Strazar, Don Lalonde, "Minimizing injection pain in local anesthesia ", CMAJ, (20121211), vol. 184, no. 18, page 2016, XP055890342
OPPOSITION- The European Agency For The Evaluation Of Medicinal Products Human Medicines Evaluation Unit, "Note for Guidance on Inclusion of Antioxidants and Antimicrobial Preservatives in Medicinal Products", EMEA Note CPMP/CVMP/QWP/115/95, (19970708), pages 1 - 4, XP055609240
OPPOSITION- Wu, Z. ; Tucker, I.G. ; Razzak, M. ; Yang, L. ; McSporran, K. ; Medlicott, N.J., "Absorption and tissue tolerance of ricobendazole in the presence of hydroxypropyl-@b-cyclodextrin following subcutaneous injection in sheep", INTERNATIONAL JOURNAL OF PHARMACEUTICS, ELSEVIER, NL, NL , (20100915), vol. 397, no. 1-2, ISSN 0378-5173, pages 96 - 102, XP027230643
OPPOSITION- Yuen Vh, Dolman Pj , "Comparison of three modified lidocaine solutions for use in eyelid anesthesia", Ophthalmic plastic and reconstructive surgery, (19990101), vol. 15, no. 2, pages 143 - 147, XP055890371
OPPOSITION- Meyer Brian K; Ni Alex; Hu Binghua; Shi Li, "Antimicrobial preservative use in parenteral products: past and present.", Journal of Pharmaceutical Sciences, American Chemical Society and American Pharmaceutical Association, US, US , (20070101), vol. 96, no. 12, doi:10.1002/jps.20976, ISSN 0022-3549, pages 3155 - 3167, XP009099142
OPPOSITION- Wilson, L. Martin, S., "Benzyl Alcohol as an Alternative Local Anesthetic", Annals of Emergency Medicine, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL, (19990501), vol. 33, no. 5, doi:10.1016/S0196-0644(99)70335-5, ISSN 0196-0644, pages 495 - 499, XP005698806
OPPOSITION- St Peter WL; Lewis MJ; Macres MG, "Pain comparison after subcutaneous administration of single-dose formulation versus multidose formulation of epogen in hemodialysis patients", American Journal of Kidney Diseases, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL, (19000101), vol. 32, no. 3, doi:10.1053/ajkd.1998.v32.pm9740164, ISSN 0272-6386, pages 470 - 474, XP028841231
OPPOSITION- Deckers Nynke, Ruigrok Catharina A, Verhoeve Hans Peter, Lourens Nicky, "Comparison of pain response after subcutaneous injection of two maropitant formulations to beagle dogs", Veterinary Record Open, (20180301), vol. 5, no. 1, doi:10.1136/vetreco-2017-000262, ISSN 2399-2050, page 262, XP055890327
OPPOSITION- LOFTSSON T, ET AL., "INTERACTIONS BETWEEN PRESERVATIVES AND 2-HYDROXYPROPYL-BETA-CYCLODEXTRIN", Journal Drug Development and Industrial Pharmacy, NEW YORK, NY, US, US , (19920101), vol. 18, no. 13, doi:10.3109/03639049209040853, ISSN 0363-9045, pages 1477 - 1484, XP008061272
SEARCH- Anonymous, "CVMP assessment report for Cerenia new route of administration (intravenous use) for the solution for injection (EMEA/V/C/000106/X/0023)", EMEA, (20150410), pages 1/12 - 2/12, URL: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/veterinary/000106/WC500189398.pdf, (20170322), XP055357742 [Y] 1-15 * page 8/12, paragraph Tolerance of excipients *
SEARCH- WU Z ET AL, "Absorption and tissue tolerance of ricobendazole in the presence of hydroxypropyl-b-cyclodextrin following subcutaneous injection in sheep", INTERNATIONAL JOURNAL OF PHARMACEUTICS, ELSEVIER, AMSTERDAM, NL, vol. 397, no. 1-2, ISSN 0378-5173, (20100915), pages 96 - 102, (20100819), XP027230643 [Y] 1-15 * page 97, column left, paragraph 3 *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents